Elena Johnson
Cancer is linked to ageing, which is a well-known risk factor. Because of the growing senior population, the number of new cancer diagnoses has increased globally. Many theories have been proposed over the years to explain this increased risk, including higher genetic and epigenetic alterations, as well as the idea of immunosenescence. The best therapeutic options for this cancer-stricken population are unknown. Older cancer patients have historically been underrepresented in clinical trials designed to establish best practises, resulting in undertreatment or higher toxicity. With this in mind, it's critical to look into new anti-cancer agents, such as immune-checkpoint inhibitors, that have recently been discovered, in order to manage these daily clinical issues and eventually combine them with alternative antiblastic drug administration strategies, such as metronomic chemotherapy.
